<DOC>
	<DOCNO>NCT01555697</DOCNO>
	<brief_summary>Cognitive training moderately effective reduce symptom improve life function schizophrenia patient . The present application develop strategy increase effectiveness cognitive training use pro-cognitive medication . Specific biomarkers study identify patient sensitive pro-cognitive medication , test feasibility use biomarkers large clinical trial medication-enhanced cognitive training schizophrenia .</brief_summary>
	<brief_title>Biomarker Strategies Medication-Enhanced Cognitive Training Schizophrenia</brief_title>
	<detailed_description>This R34 application respond PAR-09-173 , achieve first goal FOA supporting : `` development and/or pilot test new adapt intervention . '' The two overarch goal application : 1 ) test effect acute administration NMDA antagonist , memantine ( MEM ) , sensorimotor gate work memory ( WM ) schizophrenia ( SZ ) patient , 2 ) ass feasibility use MEM predictably enhance therapeutic benefit cognitive training SZ . The pharmacotherapy SZ dominate antidopaminergic drug limit clinical impact . Some form psychosocial rehabilitation , cognitive training ( CT ) , appear effectively reduce symptom improve function SZ . The premise application benefit CT SZ might enhance drug increase specific cognitive ability , include WM , even pro-cognitive drug lack clinical impact administer without CT . The main goal application develop innovative intervention strategy enhance clinical benefit CT SZ administration pro-cognitive agent biomarker-identified sensitive patient . The investigator report single dose widely use Alzheimer 's disease medication , MEM ( 20 mg p.o . ) , significantly increase prepulse inhibition ( PPI ) startle reflex healthy subject . PPI-enhancing effect MEM healthy subject associate : 1 ) increase WM ; 2 ) phenotype link high activity Val158Met COMT polymorphism . PPI consistently impair SZ patient ; low level PPI patient associate : 1 ) poor functional outcome ; 2 ) Val/Val COMT genotype . If MEM find healthy subject reproduce SZ patient , investigator detect MEM-associated improvement PPI WM , particularly among Val/Val patient . The investigator position test hypothesis acute PPI WM-enhancing effect MEM predict therapeutic benefit MEM SZ patient undergo CT . This application two aim : Aim 1 assess acute effect MEM ( 0 vs. 10 0 vs. 20 mg p.o . ) 60 SZ patient , test prediction MEM increase PPI enhance WM SZ patient , particularly characterize low basal PPI level and/or Val/Val COMT genotype . Mismatch negativity gamma band synchronization also assess potentially informative MEM-sensitive functionally relevant biomarkers . Aim 2 assess feasibility test therapeutic benefit MEM adjunct CT SZ patient , feasibility test primary hypothesis benefit predict increase PPI and/or WM SZ patient Aim 1 single dose MEM challenge . It predict subject recruitment completion arm control 12-week CT trial SZ out-patients among subject complete Aim 1 appropriate test overall effectiveness MEM adjunct CT ability predict effectiveness among biomarker-identified patient subgroup .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>A diagnosis schizophrenia schizoaffective disorder depress type Age range , Current alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>prepulse inhibition</keyword>
	<keyword>neurocognition</keyword>
	<keyword>work memory</keyword>
	<keyword>memantine</keyword>
	<keyword>MATRICS Consensus Cognitive Battery</keyword>
</DOC>